Electrophysiological measures as potential biomarkers in Huntington's disease: Review and future directions

Brain Research Reviews

Volumn 64, Issue 1, 2010, Pages 177-194

  Nguyen, Lan ^a   Bradshaw, John L ^a   Stout, Julie C ^a   Croft, Rodney J ^b   Georgiou Karistianis, Nellie ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Biomarkers; Electroencephalography; Event related potentials; Huntington's disease; Pre diagnostic Huntington's disease

Indexed keywords

COGNITIVE DEFECT; CONTINGENT NEGATIVE VARIATION; DAYTIME SOMNOLENCE; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; EVOKED BRAIN STEM AUDITORY RESPONSE; EVOKED MUSCLE RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LATENT PERIOD; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SELECTIVE ATTENTION; SENSITIVITY AND SPECIFICITY; SLEEP WALKING; VISUAL IMPAIRMENT; WORKING MEMORY;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; HUNTINGTON DISEASE;

EID: 77953358024     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2010.03.004     Document Type: Review

References (230)

1. Abbruzzese G., Berardelli A. Sensorimotor integration in movement disorders. Mov. Disord. 2003, 18:231-240.
2. Abbruzzese G., Dall'Agata D., Morena M., Reni L., Favale E. Abnormalities of parietal and preolandic somatosensory evoked potentials in Huntington's disease. Electroencephalogr. Clin. Neurophysiol. 1990, 77:340-346.
3. Andreassi J.L. Psychophysiology: Human Behaviour & Physiological Response 2000, Lawrence Erlbaum Associates, London. Fourth Edition.
4. Andrews T.C., Brooks D.J. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Mol. Med. Today 1998, 4:532-539.
5. Antal A., Beniczky S., Kincses T.Z., Jakab K., Benedek G., Vecsei L. Perceptual categorization is impaired in Huntington's disease: an electrophysiological study. Dement. Geriatr. Cogn. Disord. 2003, 16:187-192.
6. Arnulf I., Nielsen J., Lohmann E., Schieffer J., Wild E., Jennum P., Konofal E., Walker M., Oudiette D., Tabrizi S., Durr A. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65:482-488.
7. Aron A.R., Sahakian B.J., Robbins T.W. Distractibility during selection-for-action: differential deficits in Huntington's disease and following frontal lobe damage. Neuropsychologia 2003, 41:1137-1147.
8. Aylward E.H. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res. Bull. 2007, 72:152-158.
9. Aylward E.H., Codori A., Rosenblatt A., Sheer M., Brandt J., Stine O.C., Barta P.E., Pearlson G.D., Ross C.A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 2000, 15:552-560.
10. Bachoud-Levi A., Remy P., Nguyen J., Brugieres P., Lafaucheur J., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisee M., Grandmougin T., Jeny R., Bartolomeo P., Barba G.D., Gegos J., Lisovoski F., Ergis A., Pailhous E., Cesaro P., Hantraye P., Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
11. Bacon Moore A.S., Paulsen J.S., Murphy C. A test of odor fluency in patients with Alzheimer's and Huntington's disease. J. Clin. Exp. Neuropsychol. 1999, 21:341-351.
12. Band G.P., van Boxtel G.J. Inhibitory motor control in stop paradigms: review and reinterpretation of neural mechanisms. Acta Psychol. (Amst.) 1999, 101:179-211.
13. Barrios F.A., Gonzalez L., Favila R., Alonso M.E., Salgado P.M., Diaz R., Fernandez-Ruiz J. Olfaction and neurodegeneration in HD. NeuroReport 2007, 18(1):73-76.
14. Bartenstein P., Weindl A., Spiegel S., Boecker H., Wenzel R., Ceballos-Baumann A.O., Minoshima S., Conrad B. Central motor processing in Huntington's disease. A PET study. Brain 1997, 120:1553-1567.
15. Basar E., Schurmann M., Basar-Eroglu C., Karakas S. Alpha oscillations in brain functioning: an integrative theory. Int. J. Psychophysiol. 1997, 26:5-29.
16. Beal M.F., Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 2004, 5:373-384.
17. Bellotti R., De Carlo F., Massagra R., de Tommaso M., Sciruicchio V. Topographic classification of EEG patterns in Huntington's disease. Neurol. Clin. Neurophysiol. 2004, 37:1-4.
18. Beniczky S., Keri S., Antal A., Jakab K., Nagy H., Benedek G., Janka Z., Vecsei L. Somatosensory evoked potentials correlate with genetics in Huntington's disease. Neuroreport 2002, 3:2296-2298.
19. Berrios G.E., Wagle A.C., Markova I.S., Wagle S.A., Ho L.W., Rubinsztein D.C., Whittaker J., Ffrench-Constant C., Kershaw A., Rosser A., Bak T., Hodges J.R. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res. 2001, 102:217-225.
20. Berrios G.E., Wagle A.C., Markova I.S., Wagle S.A., Rosser A., Hodges J.R. Psychiatric symptoms in neurologically clinical Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr. Scand. 2002, 105:224-230.
21. Beste C., Saft C., Konrad C., Andrich J., Gold R., Falkenstein M. Error processing in Huntington's disease. PLoS ONE 2006, 1:1-5.
22. Beste C., Saft C., Yordanova J., Andrich J., Gold R., Falkenstein M., Kolev V. Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease. Neuropsychologia 2007, 45:2922-2930.
23. Beste C., Saft C., Gunturkun O., Falkenstein M. Increase cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potentials indices of auditory sensory memory and attention. J. Neurosci. 2008, 28:11695-11702.
24. Beste C., Saft C., Konrad C., Andrich J., Gold R., Falkenstein M. Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis. J. Neurophysiol. 2008, 99:1213-1223.
25. Beste C., Saft C., Konrad C., Andrich J., Gold R., Falkenstein M. Response inhibition in Huntington's disease-a study using ERPs and sLORETA. Neuropsychologia 2008, 46:1290-1297.
26. Beste C., Saft C., Konrad C., Andrich J., Habbel A., Schepers I., Jansen A., Pfleiderer B., Falkenstein M. Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry. Hum. Brain Mapp. 2008, 29:121-130.
27. Beste C., Konrad C., Saft C., Ukas T., Andrich J., Pfeiderer B., Hausmann M., Falkenstein M. Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system-evidence from event-related potentials. Exp. Neurol. 2009, 216:148-157.
28. Beste C., Willemssen R., Saft C., Falkenstein M. Error processing in normal aging and in basal ganglia disorders. Neuroscience 2009, 159:143-149.
29. Bigland K.M., Ross C.A., Langbehn D.R., Aylward E.H., Stout J.C., Queller S., Carlossi N.E., Duff K., Beglinger L.J., Paulsen J.S. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov. Disord. 2009, 24:1763-1772.
30. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
31. Blackmore L., Simpson S.A., Crawford J.R. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. J. Med. Genet. 1995, 32:358-362.
32. Blekher T.M., Yee R.D., Kirkwood S.C., Hake A.M., Stout J.C., Weaver M.R., Foroud T.M. Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vis. Res. 2004, 44:2729-2736.
33. Bloch J., Bachoud-Levi A.C., Deglon N., Lefaucheur J.P., Winkel L., Palfi S., Nguyen J.P., Bourdet C., Gaura V., Remy P., Brugieres P., Boisse M.F., Baudic S., Cesaro P., Hantraye P., Aebischer P., Peschanski M. Neuroprotective gene therapy for Huntington's disease using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum. Gene Ther. 2004, 15:968-975.
34. Boecker H., Ceballos-Baumann A., Bartenstein P., Weindl A., Siebner H.R., Fassbender T., Munz F., Schwaiger M., Conrad B. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. Brain 1999, 122:1651-1665.
35. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res. Rev. 2008, 58:209-225.
36. Bokura H., Yamaguchi S., Kobayashi S. Electrophysiological correlates for response inhibition in a Go/NoGo task. Clin. Neurophysiol. 2001, 112:2224-2232.
37. Bollen E.L., Arts R.J., Ross R.A., van der Velde E.A., Buruma O.J. Somatosensory evoked potentials in Huntington's chorea. Electroencephologr. Clin. Neurophysiol. 1985, 62:235-240.
38. Bollen E., Arts R., Ross R., van der Velde E.A., Buruma O.J. Brain reflexes and brainstem auditory evoked responses in Huntington's chorea. J. Neurol. Neurosurg. Psychiatry 1986, 49:313-315.
39. Brandt J., Shpritz B., Codori A.M., Margolis R., Rosenblatt A. Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals. J. Int. Neuropsychol. Soc. 2002, 8:918-924.
40. Bregadze N., Lavric A. ERP differences with vs. without concurrent fMRI. Int. J. Psychophysiol. 2006, 62:54-59.
41. Brotini S., Gigli G.L. Epidemiology and clinical features of sleep disorder in extrapyramidal disease. Sleep Med. 2004, 5:169-179.
42. Burke W.J., Miller J.P., Rubin E.H., Morris J.C., Coben L.A., Duchek J., Wittels I.G., Berg L. Reliability of the Washington University clinical dementia rating. Arch. Neurol. 1988, 45:31-32.
43. Bylsma F.W., Peyser C.E., Folstein S.E., Folstein M.F., Ross C., Brandt J. EEG power spectra in Huntington's disease: clinical and neuropsychological correlates. Neuropsychologia 1994, 32:137-150.
44. Bylsma F.W., Moberg P.J., Doty R.L., Brandt J. Odor identification in Huntington's disease patients and asymptomatic gene carriers. J. Neuropsychiatry Clin. Neurosci. 1997, 9:598-600.
45. Campodonico J.R., Codori A.M., Brandt J. Neuropsychological stability over 2years in asymptomatic carriers of the Huntington's disease mutation. J. Neurol. Neurosurg. Psychiatry 1996, 61:621-624.
46. Campodonico J.R., Aylward B., Codori A., Young C., Krafft L., Magdalinsky M., Ranen N., Slavney R.P., Brandt J. When does Huntington's disease begin?. J. Int. Neuropsychol. Soc. 1998, 4:467-473.
47. Castellanos F.X., Fine E.J., Kaysen D.L., Kozuch P.L., Hamburger S.D., Rapoport J.L., Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol. Psychiatry 1996, 29:33-41.
48. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23:961-969.
49. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
50. Chase T.N., Bibbiani F., Bara-Jimenez W., Dimitrova T., Oh-Lee J.D. Translating A2A antagonist KW6002 from animal models to Parkinsonian patients. Neurology 2003, 61:S107-S111.
51. Chen J., Sonsalla P.K., Pedata F., Melani A., Domenici M.R., Popoli P., Geiger J., Lopes L.V., de Mendonca A. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurol. 2007, 83:310-331.
52. Chudasama Y., Robbins T.W. Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol. Psychol. 2006, 73:19-38.
53. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 2006, 47:215-222.
54. Colebatch J.G. Bereitschaftspotential and movement-related potentials: origin, significance, and application in disorders of human movement. Mov. Disord. 2007, 22:601-610.
55. Conneally P.M. Huntington's disease: genetics and epidemiology. Am. J. Hum. Genet. 1984, 36:506-526.
56. Cooper N.R., Croft R.J., Dominey S.J., Burgess A.P., Gruzelier J.H. Paradox lost? Exploring the role of alpha oscillations during externally vs. internally directed attention and the implications for idling and inhibition hypotheses. Int. J. Psychophysiol. 2003, 47:65-74.
57. Crupi D., Ghilardi M.F., Mosiello C., Di Rocco A., Quartarone A., Bataglia F. Cortical and brainstem LTP-like plasticity in Huntington's disease. Brain Res. Bull. 2008, 75:107-114.
58. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 1993, 10:131-141.
59. Cummings D.M., Milnerwood A.J., Dallerac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:2856-2868.
60. Cummings D.M., Milnerwood A.J., Dallerac G.M., Vatsavayai S.C., Hirst M.C., Murphy K.P. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease. Brain Res. Bull. 2007, 72:103-107.
61. Cuturic M., Abramson R.K., Vallini D., Frank E.M., Shamsnia M. Sleep patterns in patients with Huntington's disease and their unaffected first-degree relatives: a brief report. Behav. Sleep Med. 2009, 7:245-254.
62. Daskalakis Z.J., Christensen B.K., Fitzgerald P.B., Roshan L., Chen R. The mechanisms of interhemispheric inhibition in the human motor cortex. J. Physiol. 2002, 543:317-326.
63. de Boo G., Tibben A., Lanser J.B.K., Jennekens-Schinkel A., Hermans J., Maat-Kievit A., Roos R.A.C. Early cognitive and motor symptoms in identified carriers of the gene for Huntington's disease. Arch. Neurol. 1997, 54:1353-1357.
64. de Boo G.M., Tibben A.A., Hermans J.A., Jennekens-Schinkel A., Maat-Kievit A., Roos R.A. Memory and learning are not impaired in presymptomatic individuals with an increased risk of Huntington's disease. J. Clin. Exp. Neuropsychol. 1999, 21:831-836.
65. de la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47:516-525.
66. de Tommaso M., de Carlo F., Difruscolo O., Massafra R., Sciruicchio V., Bellotti R. Detection of subclinical brain electrical activity changes in Huntington's disease using artificial neural networks. Clin. Neurophysiol. 2003, 114:1237-1245.
67. de Tommaso M., Difruscolo O., Sciruicchio V., Specchio N., Livrea P. Abnormalities of the contingent negative variation in Huntington's disease: correlations with clinical features. J. Neurol. Sci. 2007, 254:84-89.
68. Debener S., Ullsperger M., Siegel M., Fiehler K., von Cramon D.Y., Engel A.K. Trial-by-trial coupling of concurrent electroencephalogram and functional magnetic resonance imaging identified the dynamics of performance monitoring. J. Neurosci. 2005, 25:11730-11731.
69. Diamond R., White R.F., Myers R.H., Mastromauro C., Koroshetz W.J., Butters N., Rothstein D.M., Moss M.B., Vasterling J. Evidence of presymptomatic cognitive decline in Huntington's disease. J. Clin. Exp. Neuropsychol. 1992, 14:961-975.
70. DiProspero N.A., Chen E.Y., Charles V., Polomann M., Kordower J.H., Tagle D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 2004, 33:517-533.
71. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., Stout J.C. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 2007, 62:1341-1346. Predict-HD Investigators of the Huntington Study Group.
72. Ehle A.L., Stewart M., Lellelid N.A., Leventhal A. Evoked potentials in Huntington's disease: a comparative and longitudinal study. Arch. Neurol. 1984, 41:379-382.
73. Eichele T., Specht K., Moosmann M., Jongsma M.L., Quiroga R.Q., Nordby H., Hughahl K. Assessing the spatiotemporal evaluation of neuronal activation with single-trial event-rattled potentials and functional MRI. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17798-17803.
74. Ellenberger C.J., Petro D.J., Ziegler S.B. The visually evoked potential in Huntington disease. Neurology 1978, 28:95-97.
75. Emser W., Brenner M., Stober T., Schimrigk K. Changes in nocturnal sleep in Huntington's and Parkinson's disease. J. Neurol. 1988, 235:177-179.
76. Falkenstein M., Hoormann J., Hohnsbein J. ERP components in Go/Nogo tasks and their relation to inhibition. Acta Psychol. (Amst.) 1999, 101:267-291.
77. Farrow M., Churchyard A., Chua P., Bradshaw J.L., Chiu E., Georgiou-Karistianis N. Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease. J. Clin. Exp. Neuropsychol. 2007, 29:235-246.
78. Feigin A., Leenders K.L., Moeller J.R., Missimer J., Kuenig G., Spetsieris P., Antonini A., Eidelberg D. Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study. J. Nucl. Med. 2001, 42:1591-1595.
79. Feigin A., Ghilardi M., Huang C., Ma Y., Carbon M., Guttman M., Paulsen J.S., Ghez C.P., Eidelberg D. Preclinical Huntington's disease: compensatory brain responses during learning. Ann. Neurol. 2006, 59:53-59.
80. Ferbert A., Priori A., Rothwell J.C., Day B.L., Colebatch J.G., Marsden C.D. Interhemispheric inhibition of the human motor cortex. J. Physiol. 1992, 453:525-546.
81. Ferrante R.J. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta 2009, 1792:506-520.
82. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 1993, 119:46-71.
83. Fielding J., Georgiou-Karistianis N., Bradshaw J., Millist L., Churchyard A., White O. Accelerated time-course of inhibition of return in Huntington's disease. Behav. Brain Res. 2006, 166:211-219.
84. Filipovic S., Kostic V.S., Sternic N., Marinkovic Z., Ocic G. Auditory event-related potentials in different types of dementia. Eur. Neurol. 1990, 30:189-193.
85. Folstein S.E. Huntington's disease: a disorder of families 1989, Johns Hopkins University Press, Baltimore, M.D.
86. Georgiou N., Bradshaw J.L., Phillips J.G., Chiu E. The effect of Huntington's disease and Gilles de la Tourette's syndrome on the ability to hold and shift attention. Neuropsychologia 1995, 34:843-851.
87. Georgiou N., Bradshaw J.L., Phillips J.G., Chiu E. The effect of Huntington's disease and Gilles de la Tourette's syndrome on the ability to hold and shift attention. Neuropsychologia 1996, 34:843-851.
88. Georgiou N., Phillips J.G., Bradshaw J.L., Cunnington R., Chiu E. Impairments of movement kinematics in patients with Huntington's disease: a comparison with and without a concurrent task. Mov. Disord. 1997, 12:386-396.
89. Georgiou-Karistianis N. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?. Exp. Neurol. 2009, 220:5-8.
90. Georgiou-Karistianis N., Churchyard A., Chiu E., Bradshaw J.L. Reorientation of attention in Huntington disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 2002, 15:225-231.
91. Georgiou-Karistianis N., Sritharan A., Farrow M., Cunnington R., Stout J., Bradshaw J., Churchyard A., Brawn T.L., Chua P., Chiu E., Thiruvady D., Egan G. Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 2007, 45:1791-1800.
92. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
93. Giordani B., Berent S., Boivin M.J., Penney J.B., Lehtinen S., Markel D.S., Hollingsworth Z., Butterbaugh G., Hichwa R.D., Gusella J.F., et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch. Neurol. 1995, 52:59-64.
94. Gomez-Tortosa E., del Barrio A., Barroso T., Garcia Ruiz P.J. Visual processing disorders in patients with Huntington's disease and asymptomatic carriers. J. Neurol. 1996, 243:286-292.
95. Gomez-Tortosa E., MacDonald M.E., Friend J.C., Taylor S.A.M., Wiler L.J., Cupples A., Shrinidhi J., Guesella J., Bird E.D., Vonsattel J., Myers R.H. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 2001, 49:29-34.
96. Goodin D.S., Aminoff M.J. Electrophysiological differences between subtypes of dementia. Brain 1986, 63:552-569.
97. Hahn-Barma V., Deweer B., Durr A., Dode C., Feingold J., Pillon B., Agrid Y., Brice A., Dubois B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry 1998, 64:172-177.
98. Hamilton J.M., Murphy C., Paulsen J.S. Odor detection, learning, and memory in Huntington's disease. J. Int. Neuropsychol. Soc. 1999, 5:609-615.
99. Hansotia P., Wall R., Berendes J. Sleep disturbances and severity of Huntington's disease. Neurology 1985, 35:1672-1674.
100. Harjes P., Wanker E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 2003, 28:425-433.
101. Hayden M.R. Huntington's chorea 1981, Springer-Verlag, Berlin.
102. Heinsen H., Strik M., Bauer M., Luther K., Ulmar G., Gangnus D., Jungkunz G., Eisenmenger W., Götz M. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol. 1994, 88:320-333.
103. Holroyd C.B., Coles M.G.H. The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity. Psychological. Rev. 2002, 109:679-709.
104. Homberg V., Hefter H., Granseyer G., Strauss W., Lange H., Hennerici M. Event-related potentials in patients with Huntington's disease and relatives at risk in relation to detailed psychometry. Electroencephalogr. Clin. Neurophysiol. 1986, 63:552-569.
105. Huttunen J., Homberg V., Lange H.W. Pre- and postcentral somatosensory evoked potentials in Huntington's disease: effects of stimulus repetition rate. J. Neurol. Sci. 1993, 116:119-124.
106. Ikeda A., Shibasaki H., Kaji R., Terada K., Nagamine T., Honda M., et al. Dissociation between contingent negative variation (CNV) and Bereitschafts potential (BP) in patients with Parkinsonism. Electroencephalogr Clin. Neurophysiol. 1997, 102:142-151.
107. Izhikevich E.M., Desai N.A., Walcott E.C., Hoppensteadt F.C. Bursts as a unit of neural information: selective communication via resonance. Trends Neurosci. 2003, 26:161-167.
108. Jackson C.E., Snyder P.J. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimers Dement. 2008, 4:S137-S143.
109. Jason G.W., Suchowersky O., Pajurkova E.M., Graham L., Klimek M.L., Garber A.T., Poirier-Heine D. Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch. Neurol. 1997, 54:1081-1088.
110. Jenkins B.G., Andreassen O.A., Dedeoglu A., Leavitt B., Hayden M., Borchelt D., Ross C.A., Ferrante R.J., Beal M.F. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J. Neurochem. 2005, 95:553-562.
111. Johnson K.A., Cunnington R., Iansek R., Bradshaw J.L., Georgiou N., Chiu E. Movement-related potentials in Huntington's disease: movement preparation and execution. Exp. Brain Res. 2001, 138:492-499.
112. Johnson K.A., Cunnington R., Bradshaw J.L., Chiu E., Iansek R. Effect of an attentional strategy on movement-related potentials recorded from subjects with Huntington's disease. Mov. Disord. 2002, 17:998-1003.
113. Johnson S.A., Stout J.C., Solomon A.C., Langbehn D.R., Aylward E.H., Cruce C.G., Ross C.A., Nance M., Kayson E., Julian-Baros E., Hayden M.R., Kieburtz K., Guttman M., Oakes D., Shoulson I., Beglinger L., Duff K., Penziner E., Paulsen J.S., Predict H.D. Beyond disgust: impaired recognition of negative emotions prior to diagnosis of Huntington's disease. Brain 2007, 130:1732-1744.
114. Josiassen R.C., Shagass C., Mancall E.L., Roemer R.A. Somatosensory evoked potentials in Huntington's disease. Electroencephalogr. Clin. Neurophysiol. 1982, 54:483-493.
115. Josiassen R.C., Shagass C., Mancall E.L., Roemer R.A. Auditory and visual evoked potentials in Huntington's disease. Electroencephalogr. Clin. Neurophysiol. 1984, 57:113-118.
116. Josiassen R.C., Curry L.M., Mancall E.L., Shagass C., Roemer R.A. Relationship between evoked potential and neuropsychological findings in person "at risk" for Huntington's disease. J. Clin. Exp. Neuropsychol. 1986, 8:21-36.
117. Kassubek J., Landwehrmeyer B., Ecker D., Juengling F., Muche R., Schuller S., Weindl A., Peinemann A. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Brain Imaging 2004, 15:363-365.
118. Kassubek J., Juengling F.D., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P., Aschoff A.J., Ludolph A.C., Landwehrmeyer G.B. Tophography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 2004, 75:213-220.
119. Kassubek J., Juengling F.D., Ecker D., Landwehrmeyer G.B. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb. Cortex 2005, 15:846-853.
120. Kirkwood S.C., Siemers E., Stout J.C., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch. Neurol. 1999, 56:563-568.
121. Kirkwood S.C., Siemers E., Bond C., Conneally P.M., Christian J.C., Foroud T. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 2000, 57:1040-1044.
122. Kirkwood S.C., Siemers E., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatry 2000, 69:773-779.
123. Kirkwood S.C., Siemers E., Viken R.J., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales. J. Psychiatr. Res. 2002, 36:377-382.
124. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesseltel M., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophyiol. 2001, 86:2667-2677.
125. Klimesch W., Doppelmayr M., Hanslmayr S. Upper alpha ERD and absolute power: their meaning for memory performance. Prog. Brain Res. 2006, 159:151-165.
126. Klimesch W., Sauseng P., Hanslmayr S. EEG alpha oscillations: the inhibition-timing hypothesis. Brain Res. Rev. 2007, 53:63-88.
127. Kloppel S., Draganski B., Siebner H.R., Tabrizi S.J., Weiller C., Frackowiak R.S.J. Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain 2009, 132:1624-1632.
128. Kujala T., Tervaniemi M., Schroger E. The mismatch negativity in cognitive and clinical neuroscience: theoretical and methodological considerations. Biol. Psychol. 2007, 27:1-19.
129. Kuwert T., Noth J., Scholz D., Schwarz M., Lange H.W., Topper R., Herzog H., Aulich A., Feinedegen L.E. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov. Disord. 1993, 8:98-106.
130. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cardigan B.A., Warzecki L., Tagle D.A., Reddy H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioural and electrophysiological abnormalities in a transgenic Murine model of Huntington's disease. J. Neurosci. 2001, 21:9112-9123.
131. Lange H., Thorner G., Hopf A., Schroder K.F. Morphometric studies of the neuropathological changes in choreatic disease. J. Neurol. Sci. 1976, 28:401-425.
132. Lawrence A.D., Watkins L.H.A., Sahakian B.J., Hodges J.R., Robbins T.W. Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Brain 2000, 123:1329-1364.
133. Lazic S.E., Goodman A.O.G., Crote H.E., Blakemore C., Morton A.J., Hannan A.J., van Dellen A., Barker R.A. Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res. 2007, 1151:219-226.
134. Lefaucheur J.P., Bachoud-Levi A.C., Bourdet C., Grandmougin T., Hantraye P., Cesaro P., Degos J.D., Peshanski M., Lisovoski F. Clinical relevance of electrophysiological tests in the assessment of patients with Huntington's disease. Mov. Disord. 2002, 17:1294-1301.
135. Lefaucheur J.P., Ménard-Lefaucheur I., Maison P., Baudic S., Cesaro P., Peschanski M., Bachoud-Lévi A.C. Electrophysiological deterioration over time in patients with Huntington's disease. Mov. Disord. 2006, 21:1350-1354.
136. Leuchter A.F., Cook I.A., Hunter A., Korb A. Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence. Clin. EEG Neurosci. 2009, 40:78-83.
137. Leuthold H., Sommer W. ERP correlates of error processing in spatial S-R compatibility tasks. Clin. Neurophysiol. 1999, 110:342-357.
138. Levy L.M., Henkin R.I., Hutter A., Lin C.S., Martins D., Schellinger D. Functional MRI of human olfaction. J. Comput. Assist. Tomogr. 1997, 21:849-856.
139. Lisman J.E. Bursts as a unit of neural information: making unreliable synapses reliable. Trends Neurosci. 1997, 20:38-43.
140. Luck S.J. An introduction to the event-related potential technique 2005, MIT Press, Cambridge.
141. Macdonald V., Halliday G. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol. Dis. 2002, 10:378-386.
142. Mann D.M.A., Oliver R., Snowden J.S. The topographic distribution of brain atrophy in Huntington's disease and progressive supranulear palsy: the topographic distribution of brain atrophy in Huntington's disease and progressive supranulear palsy. Acta Neuropathol. (Berl.) 1993, 85:553-559.
143. Mason S.L., Barker R.A. Emerging drug therapies in Huntington's disease. Expert Opin. Emerg. Drugs 2009, 14:273-297.
144. Mazarakis N.K., Cybulska-Klosawicz A., Gorte H., Pang T., Van Dellen A., Kossut M., Blakemore C., Hannan A.J. Deficits in experience dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J. Neurosci. 2005, 25:3059-3066.
145. McCusker E., Richards F., Silence D., Wilson M., Trent R.J. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. J. Clin. Neurosci. 2000, 7:38-41.
146. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst. Rev. 2009, 8:1-40.
147. Michell A.W., Lewis S.J.G., Foltynie T., Barker R.A. Biomarkers and Parkinson's disease. Brain 2004, 127:1693-1705.
148. Miller B.R., Walker A.G., Shah A.S., Barton S.J., Rebec G.V. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. J. Neurophysiol. 2008, 100:2205-2216.
149. Moberg P.J., Doty R.L. Olfactory function in Huntington's disease patients and at-risk offspring. Int. J. Neurosci. 1997, 89:133-139.
150. Mohr E., Brouwers P., Claus J.J., Mann U.M., Fedio P., Chase T.N. Visuospatial cognition in Huntington's disease. Mov. Disord. 1991, 6:127-132.
151. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005, 25:157-163.
152. Mulert C., Pogarell O., Hegerl U. Simultaneous EEG-fMRI: perspectives in psychiatry. Clin. EEG Neurosci. 2008, 39:61-64.
153. Munte, T., Ridao-Alonso, M., Preinfalk, J., Jung, A., Wieringa, B., Matzke, M., Dengler, R., Johannes, S., 1997. An electrophysiological analysis of altered cognitive functions in Huntington disease. Arch. Neurol. 54, 1089-1098.
154. Naatanen R., Paavilainen P., Rinne T., Alho K. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin. Neuphysiol. 2007, 118:2544-2590.
155. Nardone R., Lochner P., Ausserer M.H., Bratti A., Tezzon B.F. Abnormal intracortical facilitation in early-stage Huntington's disease. Clin. Neurophysiol. 2007, 118:1149-1154.
156. Nieuwenhuis S., Yeung N., van den Wildenberg W., Ridderinkhof K.R. Electrophysiological correlates of anterior cingulate function in a go/no-go task: effects of response conflict and trial type frequency. Cogn. Affect Behav. Neurosci. 2003, 3:17-26.
157. Nordin S., Paulsen J.S., Murphy C. Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. J. Int. Neuropsychol. Soc. 1995, 1:281-290.
158. Noth J., Engel H., Friedemann H., Lange H.W. Evoked potentials in patients with Huntington's disease and their offspring. I. Somatosensory evoked potentials. Electroencephogr. Clin. Neurophysiol. 1984, 59:134-141.
159. Oepen G., Doerr N., Toden U. Visual (VEP) and somatosensory (SEP) evoked potentials in Huntington's chorea. Electroencephalogr. Clin. Neurophysiol. 1981, 51:666-670.
160. Paulsen J.S. Functional imaging in Huntington's disease. Exp. Neurol. 2009, 216:272-277.
161. Paulsen J.S., Ready R.E., Hamilton J.M., Mega M.S., Cummings J.L. Neuropsychiatric aspects of Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2001, 71:310-314.
162. Paulsen J.S., Zhao H., Stout J.C., Brinkman R.R., Guttman M., Ross C.A., Como P., Manning C., Hayden M.R., Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001, 57:658-662.
163. Paulsen J.S., Zimbelman J.L., Hinton S.C., Langbehn D.R., Leveroni C.L., Benjamin M.L., Reynolds N.C., Rao S.M. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. Am. J. Neuroradiol. 2004, 25:1715-1721.
164. Paulsen J.S., Magnotta V.W., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., Nopoulos P.C. Brain structure in preclinical Huntington's disease. Biol. Psychiatry 2006, 59:57-63.
165. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
166. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003, 126:1127-1135.
167. Peinemann A., Schuller S., Pohl C., Jahn T., Weindl A., Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 2005, 239:11-19.
168. Petit H., Milbled G. Anomalies of conjugate ocular movements in Huntington's chorea: application to early detection. Adv. Neurol. 1973, 1:287-294.
169. Phillips J.G., Bradshaw J.L., Chiu E., Bradshaw A. Characteristics of handwriting of patients with Huntington's disease. Mov. Disord. 1994, 9:521-530.
170. Phillips W., Shannon K.M., Barker R.A. The current clinical management of Huntington's disease. Mov. Disord. 2008, 23:1491-1504.
171. Pirogovsky E., Gilbert P.E., Jacobson M., Peavy G., Wetter S., Goldstein J., Corey-Bloom J., Murphy C. Impairments in source memory for olfactory and visual stimuli in preclinical and clinical stages of Huntington's disease. J. Clin. Exp. Neuropsychol. 2007, 29:395-404.
172. Politis M., Pavese N., Tai Y.F., Tabrizi S.J., Barker R.A., Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PETstudy. Brain 2008, 131:2860-2869.
173. Popoli P., Pezzola A., Domenici M.R., Sagratella S., Diana G., Caporali M.G., Bronzetti E., Vega J., Scotti de Carolis A. Behavioural and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease. Brain Res. Bull. 1994, 35:329-335.
174. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 2007, 81:331-348.
175. Prichep L.S. Quantitative EEG and electromagnetic brain imaging in aging and in the evolution of dementia. Ann. N. Y. Acad. Sci. 2007, 1097:156-167.
176. Reading S.A., Dziorny A.C., Peroutka L.A., Schreiber M., Gourley L.M., Yallapragada V., Rosenblatt A., Margolis R.L., Pekar J.J., Pearlson G.D., Aylward E., Brandt J., Ross C.A. Functional brain changes in presymptomatic Huntington's disease. Ann. Neurol. 2004, 55:879-883.
177. Reading S.A.J., Yassa M.A., Bakker A., Diziorny A.C., Gourley L.M., Yallapragrada V., Rosenblatt A., Margolis R.L., Aylward E.H., Brandt J., Mori S., van Zijl P., Bassett S.S., Ross C.A. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res.: Neuroimaging 2005, 140:55-62.
178. Reggio R., Pezzola A., Popoli P. The intrastratial injection of an adenosine A2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 1999, 831:315-318.
179. Roche R.A., Garavan H., Foxe J.J., O'Mara S.M. Individual differences discriminate event-related potentials but not performance during response inhibition. Exp. Brain Res. 2005, 160:60-70.
180. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21:1317-1325.
181. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
182. Rosenberg C., Nudleman K., Starr A. Cognitive evoked potentials (P300) in early Huntington's disease. Arch. Neurol. 1985, 42:984-987.
183. Rosenberg N.K., Sorensen S.A., Christensen A.L. Neuropsychological characteristics of Huntington's disease carriers: a double blind study. J. Med. Genet. 1995, 32:600-604.
184. Rossini P.M., Babiloni F., Bernardi G., Cecchi L., Johnson P.B., Malentacca A., Stanzione P., Urbano A. Abnormalities of short latency somatosensory evoked potentials in parkinsonian patients. Electroencephalogr. Clin. Neurophysiol. 1989, 74:277-289.
185. Rothlind J.C., Brandt J., Zee D., Codori A.M., Folstein S. Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease. Arch. Neurol. 1993, 50:799-802.
186. Saft C., Schüttke A., Beste C., Andrich J., Heindel W., Pfleiderer B. FMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia 2008, 46:1279-1289.
187. Savic I., Gulyas B., Larsson M., Roland P. Olfactory functions are mediated by parallel and hierarchical processing. Neuron 2000, 26:735-745.
188. Schilling G., Borchelt D.R. Identifying new therapeutics for Huntington's disease. Clin. Neurosci. Res. 2003, 3:179-186.
189. Schippling S., Schneider S.A., Bahtia K.P., Munchau A., Rothwell J.C., Tabrizi S.J., Orth M. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol. Psychiatry 2009, 65:959-965.
190. Schulz W., Dickinson A. Neuronal coding of prediction errors. Annu. Rev. Neurosci. 2000, 23:473-500.
191. Schwarz M., Block F., Topper R., Sontag K.H., Noth J. Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input. Ann. Neurol. 1992, 32:358-364.
192. Scott D.F., Healthfield K.W., Toone B., Margerison J.H. The EEG in Huntington's chorea: a clinical and neuropathological study. J. Neurol. Neurosurg. Psychiatry 1972, 35:97-102.
193. Seiss E., Praamstra P., Hesse C.W., Rickards H. Proprioceptive sensory function in Parkinson's disease and Huntington's disease: evidence from proprioception-related EEG potentials. Exp. Brain Res. 2003, 148:308-319.
194. Shoulson I. HD functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981, 31:1333-1335.
195. Siemers E., Foroud T., Bill D.J., Sorbel J., Norton J.A., Hodes M.E., Niebler G., Conneally P.M., Christian J.C. Motor changes in presymptomatic Huntington disease gene carriers. Arch. Neurol. 1996, 53:487-492.
196. Silvestri R., Raffaela M., De Domenico P., Tisano A., Mento G., Casella C., Tripoli M.C., Serra S., Di Perri R. Sleep features in Tourette's syndrome, neuroaccantocytosis and Huntington's chorea. Neurophysiol. Clin. 1995, 25:66-77.
197. Sishta S.K., Troupe A., Marszalek K.S., Kremer L.M. Huntington's chorea: an electrocephalographic and psychometry study. Electroencephalogr. Clin. Neurophysiol. 1974, 36:387-393.
198. Skinner R.D., Miyazato H., Garcia-Rill E. The sleep-state dependent P50 auditory evoked potential in neuropsychiatric diseases. Int. Congr. Series 2002, 1232:813-825.
199. Smith M.A., Brandt J., Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000, 403:544-549.
200. Snowden J.S., Craufurd D., Thompson J., Neary D. Psychomotor, executive and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol. 2002, 24:133-145.
201. Solomon A.C., Stout J.C., Johnson S.A., Langbehn D.R., Aylward E.H., Brandt J., Ross C.A., Beglinger L., Hayden M.R., Kieburtz K., Kayson E., Julian-Baros E., Duff K., Guttman M., Nance M., Oakes D., Shoulson I., Penziner E., Paulsen J.S. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007, 45:1767-1776.
202. Sprengelmeyer R., Lange H., Hömberg V. The pattern of attentional deficits in Huntington's disease. Brain 1995, 118:145-152.
203. Sritharan, A., Egan, G., Johnston, L., Horne, M., Bradshaw, J., Bohanna, I., Asadi, H., Cunnington, R., Churchyard, A., Chua, P., Farrow, M., Georgiou-Karistianis, N., 2010. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J. Neurol. Neurosurg. Psychiatry 81, 257-262.
204. Starkstein S.E., Brandt J., Bylsma F., Peyser C., Folstein M., Foltein S.E. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neurodiology 1992, 34:487-489.
205. Starr A. A disorder of rapid eye movements in Huntington's chorea. Brain 1967, 90:545-564.
206. Strauss M.E., Brandt J. Are there neuropsychologic manifestations of the gene for Huntington's disease in asymptomatic, at-risk individuals?. Arch. Neurol. 1990, 47:905-908.
207. Streletz L.J., Reyes P.F., Zalewska M., Katz L., Fariello R.G. Computer analysis of EEG activity in dementia of the Alzheimer's type and Huntington's disease. Neurobiol. Aging 1990, 11:15-20.
208. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999, 59:355-396.
209. Swerdlow N.R., Benbow C.H., Ziszook S., Geyer M.A., Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol. Psychiatry 1993, 33:298-301.
210. Swerdlow N.R., Paulsen J., Braff D.L., Butters N., Geyer M.A., Swenson M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosur. Psychiatry 1995, 58:192-200.
211. Taylor N., Bramble D. Sleep disturbance and Huntington's disease. Br. J. Psychiatry 1997, 171:393.
212. A novel gene containing a trinucleotide repeat that is expanded and unstable in HD chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
213. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., McCusker E., Frackowiak R.S.J. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125:1815-1828.
214. Thiruvady D.R., Georgiou-Karistianis N., Egan G.F., Ray S., Sritharan A., Farrow M., Churchyard A., Chua P., Bradshaw J.L., Brawn T.L., Cunnington R. Functional connectivity of the prefrontal cortex in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:127-133.
215. Thompson P.D., Berardelli A., Rothwell J.C., Day B.L., Dick J.P.R., Benecke R., et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988, 111:223-244.
216. Topper R., Schwartz M., Podoll K., Domges F., Noth J. Absence of frontal somatosensory evoked potentials in Huntington's disease. Brain 1993, 116:87-101.
217. Uc E.Y., Skinner R.D., Rodnitzky R.L., Garcia-Rill E. The midlatency auditory evoked potential P50 is abnormal in Huntington's disease. J. Neurol. Sci. 2003, 212:1-5.
218. van Dellen A., Grote H.E., Hannan A.J. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin. Exp. Phamacol. Physiol. 2005, 32:1007-1019.
219. van der Hiele K., Jurgens C.K., Vein A.A., Reijntjes R.H.A.M., Witjes-Ane M.W., Roos R.A.C., van Dijk G., Middlekoop H.A.M. Memory activation reveals abnormal EEG in preclinical Huntington's disease. Mov. Disord. 2007, 22:690-695.
220. Verny C., Allain P., Prudean A., Malinge M.C., Gohier B., Scherer C., Bonneau D., Dubas F., Gall D.L. Cognitive changes in asymptomatic carriers of Huntington disease mutation gene. Eur. J. Neurol. 2007, 14:1344-1350.
221. Walker A.G., Miller B.R., Fritsch J.N., Barton S.J., Rebec G.V. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. J. Neurosci. 2008, 28:8973-8982.
222. Wetter S., Peavy G., Jacobson M., Hamilton J., Salmon D., Murphy C. Olfactory and auditory event-related potential in Huntington's disease. Neuropsychology 2005, 19:428-436.
223. Wiegand M., Moller A.A., Lauer C.J., Stolz S., Schreiber W., Dose M., Krieg J.C. Nocturnal sleep in Huntington's disease. J. Neurol. 1991, 28:203-208.
224. Wiegand M., Moller A.A., Shreiber W., Lauer C., Krieg J. Brain morphology and sleep EEG in patients with Huntington's disease. Eur. Arch. Psychiatr. Clin. Neurosci. 1991, 24:148-152.
225. Witjes-Ane M.W., Vegter-van der Vlis M., van Vugt J.P.P., Lanser J.B.K., Hermans J., Zwinderman A.H., van Ommen G.B., Roos R.A.C. Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study. J. Neuropsychiatr. Clin. Neurosci. 2003, 15:7-16.
226. Wolf R.C., Vasic N., Schönfeldt-Lecuona C., Landwehrmeyer G.B., Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 2007, 130:2845-2857.
227. Wolf R.C., Sambataro F., Vasic N., Schonfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load. Eur. J. Neurol. 2008, 15:1180-1190.
228. Wolf R.C., Sambataro F., Vasic N., Schönfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp. Neurol. 2008, 213:137-144.
229. Wolf R.C., Vasic N., Schonfeldt-Lecuona C., Ecker D., Landwehrmeyer G.B. Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum. Brain Mapp. 2009, 30:327-339.
230. Yordanova J., Falkenstein M., Hohnsbein J., Kolev V. Parallel systems of error processing in the brain. Neuroimage 2004, 22:590-602.